Literature DB >> 21997661

Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study.

Susan E Coffin1, Kateri Leckerman, Ron Keren, Matthew Hall, Russell Localio, Theoklis E Zaoutis.   

Abstract

BACKGROUND: Antiviral therapy reduces symptom duration and hospitalization risk among previously healthy and chronically ill children infected with seasonal influenza. The effect of oseltamivir on outcomes of hospitalized children is unknown. The primary objective of this study was to determine whether oseltamivir improves outcomes of critically ill children hospitalized with influenza.
METHODS: We performed a retrospective cohort study of children with influenza infection admitted to a pediatric intensive care unit during 6 consecutive winter seasons (2001-2007). We used the Pediatric Health Information System database, which contains resource utilization data from 41 children's hospitals. We matched oseltamivir-treated patients with oseltamivir-nontreated patients by the probability of oseltamivir exposure using a propensity score we derived from patient and hospital characteristics. We subsequently compared the outcomes of critically ill children treated with oseltamivir within 24 hours of admission with propensity score matched children who were not treated with oseltamivir.
RESULTS: We identified 1257 children with influenza infection, 264 of whom were treated with oseltamivir within 24 hours of hospital admission. Multivariable analysis of 252 oseltamivir-treated patients and 252 propensity score-matched untreated patients demonstrated that patients treated with oseltamivir experienced an 18% reduction in total hospital days (time ratio: 0.82, P = 0.02), whereas intensive care unit stay, in-hospital mortality, and readmission rates did not differ.
CONCLUSION: For critically ill children infected with seasonal influenza, treatment with oseltamivir within 24 hours of hospitalization was associated with a shorter duration of hospital stay. Additional study is needed to determine the effect of delayed initiation of oseltamivir on clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997661      PMCID: PMC3426912          DOI: 10.1097/INF.0b013e318232ede9

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  32 in total

1.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

2.  Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2 -Hong Kong infection. A controlled double-blind study.

Authors:  A W Galbraith; J S Oxford; G C Schild; C W Potter; G I Watson
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

3.  Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza.

Authors:  Y Togo; R B Hornick; V J Felitti; M L Kaufman; A T Dawkins; V E Kilpe; J L Claghorn
Journal:  JAMA       Date:  1970-02-16       Impact factor: 56.272

4.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

5.  Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980-1997.

Authors:  C Feudtner; D A Christakis; F A Connell
Journal:  Pediatrics       Date:  2000-07       Impact factor: 7.124

6.  Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals.

Authors:  Jay G Berry; David E Hall; Dennis Z Kuo; Eyal Cohen; Rishi Agrawal; Chris Feudtner; Matt Hall; Jacqueline Kueser; William Kaplan; John Neff
Journal:  JAMA       Date:  2011-02-16       Impact factor: 56.272

7.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

8.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Authors:  K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

9.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Authors:  F G Hayden; J J Treanor; R S Fritz; M Lobo; R F Betts; M Miller; N Kinnersley; R G Mills; P Ward; S E Straus
Journal:  JAMA       Date:  1999-10-06       Impact factor: 56.272

10.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

Authors:  Laurent Kaiser; Cynthia Wat; Tracy Mills; Paul Mahoney; Penelope Ward; Frederick Hayden
Journal:  Arch Intern Med       Date:  2003-07-28
View more
  25 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 2.  Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.

Authors:  Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann
Journal:  Ann Intern Med       Date:  2012-02-27       Impact factor: 25.391

Review 3.  Influenza and the use of oseltamivir in children.

Authors:  Ergin Çiftçi; Adem Karbuz; Tanıl Kendirli
Journal:  Turk Pediatri Ars       Date:  2016-06-01

4.  Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia.

Authors:  Ikwo K Oboho; Anna Bramley; Lyn Finelli; Alicia Fry; Krow Ampofo; Sandra R Arnold; Wesley H Self; Derek J Williams; D Mark Courtney; Yuwei Zhu; Evan J Anderson; Carlos G Grijalva; Jonathan A McCullers; Richard G Wunderink; Andrew T Pavia; Kathryn M Edwards; Seema Jain
Journal:  Open Forum Infect Dis       Date:  2016-12-27       Impact factor: 3.835

5.  The burden of influenza in young children, 2004-2009.

Authors:  Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Beverly M Snively; Cynthia K Suerken; Caroline B Hall; Geoffrey A Weinberg; Sandra S Chaves; Yuwei Zhu; Monica M McNeal; Carolyn B Bridges
Journal:  Pediatrics       Date:  2013-01-06       Impact factor: 7.124

Review 6.  Influenza vaccination and treatment in children with neurologic disorders.

Authors:  Fiona Havers; Alicia Fry; Georgina Peacock; Lyn Finelli
Journal:  Ther Adv Vaccines       Date:  2014-07

7.  Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A*.

Authors:  Carl O Eriksson; Dionne A Graham; Timothy M Uyeki; Adrienne G Randolph
Journal:  Pediatr Crit Care Med       Date:  2012-11       Impact factor: 3.624

8.  Morbidity of peripherally inserted central catheters in pediatric complicated appendicitis.

Authors:  Jason P Sulkowski; Lindsey Asti; Jennifer N Cooper; Brian D Kenney; Mehul V Raval; Shawn J Rangel; Katherine J Deans; Peter C Minneci
Journal:  J Surg Res       Date:  2014-03-13       Impact factor: 2.192

9.  Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation.

Authors:  Chris Feudtner; James A Feinstein; Wenjun Zhong; Matt Hall; Dingwei Dai
Journal:  BMC Pediatr       Date:  2014-08-08       Impact factor: 2.125

10.  Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico.

Authors:  Gerardo Chowell; Cécile Viboud; Lone Simonsen; Mark A Miller; Santiago Echevarría-Zuno; Margot González-León; Víctor H Borja Aburto
Journal:  BMC Infect Dis       Date:  2012-04-20       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.